TB-500 is commonly grouped with recovery-oriented peptide discussions.
Evidence level: Public discussion / regulatory watch
Sources: U.S. Food and Drug Administration
Avoid implying efficacy unless a specific source supports the precise claim.
Research peptide
TB-500
TB-500 appears in online recovery and performance discussions. The site tracks public claims and regulatory references without turning those claims into treatment guidance.
Regulatory watch
Last reviewed 2026-06-30
Next review 2026-07-24
Evidence snapshot
Keep this page source-led and refresh it whenever FDA meeting materials or new public regulatory records appear.
Often discussed alongside injury recovery topics.
Scheduled for FDA advisory committee discussion in July 2026.
High risk of overclaiming in generated content.
Tracked claims
The next editorial update should check the FDA advisory committee outcome.
Evidence level: Primary regulatory
Sources: U.S. Food and Drug Administration
Use the date-based review queue to prevent stale regulatory copy.
Sources on this page
Source records are stored in the repo and linked from each claim.
July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
FDA advisory committee meeting notice listing multiple peptide bulk substances scheduled for discussion.
Certain bulk drug substances for use in compounding may present significant safety risks
FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.